Hemogenyx Pharmaceuticals Share Discussion Threads

[tsmith2] 21/10/2019 11:29

Peterhouse Capital@peterhousecap·2h#PCAP Client @HemoGenyx Announces it will present at the NY Stem Cell Foundation conference @nyscf The conference will be held on October 22-23 at The Rockefeller University, New York https://bit.ly/2Dc7oSk See more here: https://bit.ly/2VZuzbG #HEMO

[idontflykathy] 21/10/2019 11:21

Bought 85K share this morning at 2.05p - just for trading.

[purple11] 21/10/2019 10:08

Presentation at New York Stem Cell Foundation conference

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it will present at the New York Stem Cell Foundation (NYSCF) conference. The conference will be held on October 22-23 at The Rockefeller University, New York (

Hemogenyx's poster presentation is entitled 'Efficacy of FLT3-CD3 bispecific antibody against AML in humanized mouse models'. The presentation will highlight the unique properties of Hemogenyx's main product candidate CDX bispecific antibody that is being developed by the Company for the treatment of relapsed/refractory acute myeloid leukemia (AML) and conditioning of bone marrow transplants. It will also demonstrate the utility of the humanized mice developed by Immugenyx, LLC, a wholly-owned subsidiary of Hemogenyx, in drug development.

The NYSCF Conference is the leading scientific meeting on translational stem cell research. It convenes over 500 participants from academia, industry, government, non-profits, and patient groups. This year's keynote speeches will be given by Nobel Laureate Shinya Yamanaka, MD, PhD, of Kyoto University and Hans Clevers, MD, PhD, of Hubrecht Institute, Utrecht University. Additional speakers include world-renowned, multi-disciplinary scientists who will present their latest findings about the transformative impact of stem cell research on numerous diseases with high unmet needs

[davevt] 18/10/2019 13:10

The doctor is blocking investors on twitter, and I'm a troll warning you all eh?

[idontflykathy] 17/10/2019 18:20

Look at NFX!! 17% today!!!

Ok enough!!

I almost recovered my loss from HEMO.

Ok enough...

[idontflykathy] 17/10/2019 11:50

He also blocked my friend too who asked similar status.

BTW - My decision of investing in NFX already reaping reward with 15% up in a week.

I would put here in HEMO soon as this is tempting level. Just to trade.. not investing.

[johntopdog] 16/10/2019 12:43

Haha looks like he blocked me for asking for an update !

[on target] 16/10/2019 12:24

Looks still there to me?

[johntopdog] 16/10/2019 12:19

I see the DR is no longer on Twitter!

[krowelet] 16/10/2019 09:29

Agreed, that is a positive way of looking at it, at least they have not sold any.

[on target] 16/10/2019 09:03

Management do own 1/3rd of the company's shares already, or at least some of them do.
Would be good to see the likes of Feldmann buying a few.

[krowelet] 16/10/2019 08:48

very little management buying history since listing over 2 years ago, in fact very little of anything whatsoever.

[idontflykathy] 16/10/2019 08:19

Dave - You’re a troll, everyone aware here and other board.

Why can’t you just keep within yourself ?
Your further message or reply here will
not be entertained.

Thank you!

[davevt] 15/10/2019 13:39

Kathy gets it at last.

[davevt] 15/10/2019 13:38

Kathy gets it at last.

[johntopdog] 11/10/2019 18:25

Looks like you went into a right donkey in nuformix kathy..

[idontflykathy] 11/10/2019 13:33

Thank you Target - No, sorry I didn't.

Looks very informative. Let me go through it. Thanks!

[purple11] 11/10/2019 13:28

Peer-group review
Hemogenyx operates in an area of intense focus for industry. Therefore, we compiled a peer group of ex-UK development-stage companies which operate within similar treatment areas to Hemogenyx (i.e. treatment of blood cancers or alternate therapies for bone marrow transplants). The median-market capitalisation of the peer-group is �129.1m, over 10-fold higher than that of Hemogenyx (Table 1).
We then compared Hemogenyx to several AIM or LSE standard-listed drug developers at a preclinical stage (Table 2). As is demonstrated, Hemogenyx�s current market capitalisation is half that of the peer-group median of c.�17.2m. Given that the Company has multiple assets, each with collaboration agreements, we believe that this price discrepancy is unjustified and that Hemogenyx shares consequently have considerable upside potential.
Finally, we note that the two investments by Orgenesis into the Immugenyx and Hemogenyx-Cell subsidiaries are on pre-money valuations of US$8m and US$12m respectively. The combined value of these two subsidiaries is c.20% higher than the current market capitalisation of Hemogenyx. Note this US$20m valuation does not include the CDX Ab platform, the Group�s leading technology, over which Hemogenyx is in advanced discussions with a potential partner.
We feel these points highlight the undervalued nature of this stock.

[on target] 11/10/2019 13:25

Did you read this Idont?



Yes it's from HEMO's broker share price Angel, but it does provide a lot of detailed information on what the company is doing and what their objectives are.

[purple11] 11/10/2019 13:19

always the way no one want to buy while its cheap but the board comes alive and everyone piles in once its doubled in price.its what makes these bbs so rubbish.

[idontflykathy] 11/10/2019 13:18

It's okay Purple you filtered me.

I just gave my honest opinion after investing here for almost 2 years.

It's not rocket science to u'stand how's company doing and what's their objective.

Here HEMO is just waste of everyone's time. It should fold to be honest with no meaningful to give. Better to continue work for subsidiaries.

[purple11] 11/10/2019 13:14

vlx is 90p today that would do!comparing the two is nonsensical,.